OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCC

November 4th 2022

Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. McKay on Recent Advancements in the Frontline Treatment of Metastatic RCC

November 4th 2022

Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.

Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC

November 3rd 2022

Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.

Dr. Miron on Resistance Mechanisms to FGFR Inhibitors in Cholangiocarcinoma

November 3rd 2022

Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Dr. Barzi on the Need for More Sensitive MRD Testing in CRC

November 3rd 2022

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated Melanoma

November 3rd 2022

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs

November 3rd 2022

Zofia Piotrowska, MD, discusses the management of paronychia associated with EGFR TKIs.

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

November 3rd 2022

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Dr. Binder on Key Trials Improving the Treatment Landscape for Endometrial Cancer

November 3rd 2022

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.

Dr. Saba on the Investigation of Pembrolizumab Plus Cabozantinib in HNSCC

November 2nd 2022

Nabil Saba, MD, FACP, discusses the evaluation of pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

November 2nd 2022

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.

Dr. Klempner on the Unique Trial Design of KRYSTAL-1 in CRC

November 2nd 2022

Sam Klempner, MD, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial in colorectal cancer.

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

Dr. Goyal on the Potential Benefits of RLY-4008 in FGFR2+ Cholangiocarcinoma

November 1st 2022

Lipika Goyal, MD, discusses the potential for RLY-4008, an agent under exploration in patients with cholangiocarcinoma harboring an FGFR2 rearrangement or fusion.

Dr. Berg on the Role of the PEACE-1 and ARASENS Trials in Expanding mHSPC Treatment

November 1st 2022

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

November 1st 2022

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Dr. Salani on the Role of Molecular Profiling in Endometrial Cancer Treatment

November 1st 2022

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

Dr. Susanibar-Adaniya on the Evolution of Combination Therapies in Multiple Myeloma

October 31st 2022

Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.

Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification

October 31st 2022

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.